Bayer announced the initiation of the FIND-CKD study, a multicenter, randomized, double-blind, placebo-controlled Phase III study for an investigational new use of KERENDIA® (finerenone) in addition to guideline-directed therapy, on the progression of chronic kidney disease (CKD) in patients with nondiabetic CKD.1 The primary objective of the study is to demonstrate superiority of finerenone over placebo in delaying the progression of CKD in these patients. The primary outcome measure is the mean rate of change in kidney function over time (estimated glomerular filtration rate [eGFR] slope) from baseline to month 32. KERENDIA – a nonsteroidal mineralocorticoid receptor antagonist (MRA) – was approved in the United States on July 9, 2021, to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction and hospitalization for heart failure in adult patients with CKD associated with type 2 diabetes (T2D).6 The KERENDIA label contains a Warning and Precaution that KERENDIA can cause hyperkalemia.6 For more information, see “Important Safety Information” .